menu search

Biopharma Co.’s Shares Triple in Value on US$5B License Deal

Biopharma Co.’s Shares Triple in Value on US$5B License Deal
Source: Streetwise Reports (12/7/22) Summit Therapeutics Inc. shares traded 194% higher yesterday after the company reported it entered into an in-license agreement with Akeso Inc. for its breakthrough bispecific antibody ivonescimab, which combines a blockade of PD-1 with an anti-VEGF into a single molecule designed to target cancer. Summit has agreed to pay Akeso an upfront […]... Read More
Posted: Dec 8 2022, 13:30
Author Name: investmacro
Views: 112589

Search within

Pages Search Results: